- Trxade Group Inc. is a growing B2B pharmaceutical network that provides solutions to small healthcare businesses, care providers and medical patients through growing optimization of remote-access health services
- Amid the sweep of the global COVID-19 pandemic, Trxade Group has continued to build its vision of enabling the health industry to operate transparently and effectively even as the importance of changing remote-access medicine models grows
- Trxade Group recently began receiving research report coverage from investment services firm Taglich Brothers, Inc. as part of ongoing brand-building efforts
- The company also recently announced that experienced healthcare market advisory professional Ashton Maaraba has been named president of Trxade Group’s Bonum Health telemedicine practice and will guide new patient acquisition
Growing prescription drug delivery and healthcare services innovator Trxade Group (NASDAQ: MEDS) continues to nurture a brand built on the vision of officers intent on providing affordability, transparency and equal access to medical community patients through effective technology. The company recently announced that investment services firm Taglich Brothers, Inc. has begun providing coverage to Trxade through its research division (http://ibn.fm/sSOt8).
Trxade’s efforts to expand its network of independent pharmacies and empower them to better deliver medications regardless of competition from larger retail chains have resulted in an upswell of brand-building and marketing outreach during the past several months.
After Trxade’s acquisition of Internet drug outlet company Community Specialty Pharmacy, LLC, (http://ibn.fm/wrNq4) the company began building a remote-access “secure virtual examination room” for patient-physician consultation through a “Health Hub” initiative that partners with the company’s drug delivery services (http://ibn.fm/3mHKC).
Trxade then began listing its common stock on The NASDAQ Capital Market in February as part of its efforts to increase its visibility, stability and ability to attract new investment (http://ibn.fm/uTO4r), even as the novel coronavirus pandemic was beginning to make itself known throughout the world. Trxade helped respond to concerns about limited testing for the new virus by rolling out an FDA-approved rapid point-of-care skin prick test to help medical professionals triage patients with potential COVID symptoms (http://ibn.fm/0Oknn).
Trxade’s developments are helping to position the company to deliver value to the health care market in coming days as nations recover from their initial shock at seeing populations decimated by the pandemic and begin working with confidence on providing health solutions and solutions that address economic and lifestyle needs.
“We believe our platform will become even more important for our customers in the years to come. We have a clear vision of our strategy and the opportunities ahead and look forward to another successful year of growth,” Board Chairman and CEO Suren Ajjarapu stated earlier this year in a report on the company’s 2019 achievements (http://ibn.fm/jA8tM).
The Taglich Brothers coverage involves an agreement for Taglich to create and disseminate research reports on Trxade and its market. Trxade has paid for the initial two months, which will begin reporting in September, and will begin paying a monthly service amount for ongoing reporting after that initial period has expired.
Trxade also recently announced the appointment of former AshHealth healthcare market advisory firm President Ashton Maaraba as president of Trxade Group’s Bonum Health telemedicine practice.
Maaraba has over 20 years of experience in developing and directing strategic national sales, marketing and operating initiatives in ever-changing, dynamic environments, according to the company, and will work to help build long-term shareholder value by welcoming a growing number of patients under the Bonum Health Hub platform.
“Ashton is an intuitive leader with acute business acumen and expertise in channel development and market development,” Trxade Group CEO Suren Ajjarapu stated in describing the company’s forward strategy (http://ibn.fm/8hFn9). “I am confident in his ability to drive widespread adoption of Bonum Health amongst both employers seeking to provide unique healthcare perks to their workers as well as to individuals seeking a low-cost, convenient way to speak with a doctor.”
For more information, visit the company’s website at www.TrxadeGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
